Our aim was to evaluate the protective effect of berberine on 7,12-dimethylbenz [a]anthracene (DMBA)-induced chromosomal aberrations and micro-nucleated polychromatic erythrocytes (MnPCEs) frequency in bone marrow cells of golden Syrian hamsters. The anti-clastogenic effect of berberine (50 mg ⁄ kg b.w. p.o.) was also assessed by measuring the status of phase II detoxification enzymes and oxidative stress, as biochemical endpoints, during DMBA (30 mg ⁄ kg b.w. i.p.) induced clastogenesis. Marked chromosomal aberrations, increased MnPCEs frequency and enhanced status of lipid peroxidation, antioxidants and phase I and II detoxification enzymes were noticed in hamsters treated with DMBA alone. Oral pretreatment with berberine for 5 days to DMBA-treated hamsters significantly reduced the frequency of MnPCEs and chromosomal abnormalities as well as reversed the status of lipid peroxidation, antioxidants and phase I and II detoxification enzymes. The present study thus suggests that berberine has potent anti-clastogenic potential against DMBA-induced clastogenesis, which is probably due to its anti-lipid peroxidative potential and effect on modulation of phase I and II detoxification cascade.Somatic cell mutation plays a crucial role in the initiation and promotion of carcinogenesis. Polycyclic aromatic hydrocarbons exert mutagenic and carcinogenic effects in biological systems if they are metabolically activated to more reactive forms [1]. 7,12-Dimethylbenz[a]anthracene (DMBA), a potent and best characterised organ-specific carcinogen, attacks DNA through its active metabolite 4-dihydrodiol-1,2-epoxide. DMBA firmly binds to epidermal DNA and generates a complex DNA adduct profile [2]. DMBA is therefore widely used to induce clastogenesis in experimental animals.The investigation of new anti-clastogenic and anti-carcinogenic compounds is essential in the modern human civilization due to rise in undesirable genetic mutations and increase in cancer risk [3]. In vivo models with laboratory animals are the reliable approaches to predict the clastogenic or anti-clastogenic potential of natural or synthetic agents [4]. Bone marrow cells were commonly employed as a tool for the evaluation of clastogenic and anti-clastogenic efficacy of carcinogens and anti-cancer compounds, respectively. An abnormality in chromosomal structure (translocation, deletion, duplication) and chromosomal number due to exposure to chemical carcinogen and ⁄ or mutagen is associated with increased risk of cancer and in the progression of neoplastic transformation [5]. Gaizev et al. and Hayashi et al. reported that measurement of micronuclei in polychromatic erythrocytes is suitable to identify a mutagenic substance due to the reason that their macronucleus is extruded in the processes of their formation from erythroblasts [6,7]. Also, it is easy to examine chromosomal aberrations in the metaphase stage due to its compact arrangement [8].Though a battery of genotoxicity tests is used to evaluate the anti-clastogenic effect of medicinal plant...